UK’s NICE recommends Brukinsa to treat adults with CLL
NICE has released the final draft guidance (FDG) that suggests Brukinsa as a recommended treatment for eligible adults with untreated CLL if there is a 17p deletion or
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted in favour of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) for treating triple-class exposed relapsed or refractory multiple myeloma.
PCI will be responsible for the formulation, packaging, and distribution of a siRNA-based investigational injectable treatment for inflammatory dermatological conditions. The organisation will carry out all these activities
CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced
The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not
CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are